Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy

Izumi, Kouji; Mizokami, Atsushi; Sugimoto, Kazuhiro; Narimoto, Kazutaka; Miwa, Shuhei; Maeda, Yuji; Kadono, Yoshifumi; Takashima, Mitsuhiro; Koh, Eitetsu; Namiki, Mikio

doi:10.1016/j.urology.2009.01.046

Cited by 28 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The control group was set but not randomized. 7 Taxel et al 18 recently reported the results of a randomized, double-blind, placebo-controlled trial. In their study, 40 men receiving luteinizing hormone-releasing hormone agonist for 6 months for locally advanced PCa were randomized in the risedronate administration group and the control group.…”

Section: Discussionmentioning

confidence: 99%

“…This prospective observational study was conducted with the same patient selection criteria as used previously. 7 However, some patients did not complete 24 months of the study, and 44 of 96 patients initially enrolled were available for analysis. Patients diagnosed with histologically proven PCa and treated with ADT (combination of luteinizing hormone-releasing hormone agonist and antiandrogens or monotherapy of luteinizing hormone-releasing hormone agonist) or newly diagnosed with PCa and scheduled for treatment with ADT were enrolled in this study.…”

Section: Study Populationmentioning

confidence: 99%

“…We reported previously that bone mineral density (BMD) of the risedronate administration group recovered significantly after 12 months compared with the control group. 7 Although long-term and continuous ADT was shown to be highly efficacious in localized PCa, 8 there have been no reports regarding the treatment with risedronate over periods longer than 12 months. This study extended our earlier series to prolong follow-up, and allowed evaluation of whether risedronate recovered decreases in BMD of the lumbar spine caused by ADT through 24 months.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Izumi

Mizokami

Sugimoto

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) for prostate cancer (PCa) causes bone loss. Although we reported previously that risedronate significantly recovers bone mineral density (BMD) for up to 12 months, there have been no reports with longer follow-up periods to date. This study extended our earlier series extending the follow-up period to 24 months. Eligible patients had histologically confirmed PCa without lumbar spine metastasis and underwent ADT. Lumbar spine BMD, urinary deoxypyridinoline (uDPD) and serum bone alkaline phosphatase were measured at 6, 12 and 24 months. Among the total of 96 patients, we analyzed 26 and 18 patients in risedronate administration and control groups, respectively. BMD relative to the young adult mean ratio, uDPD and serum bone alkaline phosphatase of the risedronate administration group recovered significantly after 24 months compared with the control group (Po0.0001, P ¼ 0.0001, and Po0.0001, respectively). Transient blurred vision, malaise and vertigo were observed in 1 patient each among the 46 patients treated with risedronate within 28 days after first administration. Oral administration of risedronate is safe and effective for the recovery of ADT-induced bone loss in PCa patients even at 24 months after commencement of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Izumi

Mizokami

Sugimoto

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…[15] reported a prospective 1-year observational study of 60 Japanese men receiving ADT and daily risedronate or ADT alone. The study comprised men on ADT (mean of 15.5 months) and those who were newly diagnosed and scheduled to receive ADT.…”

Section: Discussionmentioning

confidence: 99%

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

et al. 2010

View full text Add to dashboard Cite

including 40 men aged ≥ 55 years receiving LHRH-agonist treatment for 6 months for locally advanced prostate cancer. Bone mineral density (BMD) of the lumbar spine, femoral neck, and total hip was measured every 6 months. In addition, bone turnover markers including N-telopeptide, serum C-telopeptide and procollagen peptide, and 25-OH vitamin D and intact parathyroid hormone were measured at baseline and at 6 months.

show abstract

“…Denosumab (at a lower dose and treatment frequency compared with advanced oncology settings) is also approved in the United States and the European Union to treat postmenopausal osteoporosis in women at high risk for fracture, and to treat bone loss associated with hormonal therapy for PC in men at high risk for fracture (defined as age >70 years, osteopenia, or history of osteoporotic fracture) [Amgen Europe B.V., 2010]. Although the mechanisms of action of denosumab and BPs are different, both classes of agents inhibit pathologic bone turnover, resulting in reduced skeletal morbidity.In addition to their established role for preserving skeletal integrity in patients with malignant bone disease, bone-modifying agents also help preserve BMD and can reduce fracture risk during cancer treatment, most notably during ADT for PC [Bhoopalam et al 2009; Casey et al 2010;Greenspan et al 2007;Israeli et al 2007;Izumi et al 2009;Planas et al 2009;Ryan et al 2006;Smith et al 2001Smith et al , 2003Smith et al , 2009Taxel et al 2010]. Emerging evidence also suggests that bonemodifying agents may delay the progression of bone lesions and help delay the development of skeletal and other metastases [Lipton et al 2003 2008; Smith et al 2012; Zaghloul et al 2010], potentially through making the bone microenvironment less conducive to tumor growth.…”

mentioning

confidence: 99%

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Aapro¹,

Saad²

2012

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Many patients with advanced genitourinary malignancies develop bone metastases, which can lead to potentially debilitating skeletal complications. Moreover, age-related bone loss and cancer treatments such as hormonal therapy for prostate cancer can weaken bone, placing patients at risk for osteoporotic fractures in addition to skeletal-related events (SREs) from bone metastases. Zoledronic acid, a bisphosphonate, is approved worldwide to reduce the risk of SREs in patients with bone metastases from solid tumors or bone lesions from multiple myeloma. Zoledronic acid, although underutilized in genitourinary malignancies, has long been the mainstay of treatment in patients with bone metastases, and can also help preserve bone during anticancer therapy. Recently, denosumab, a monoclonal antibody directed against the receptor activator of nuclear factor kappa-B ligand, was approved in the United States and the European Union for reducing the risk of SREs in patients with bone metastases from solid tumors. Denosumab (at a lower dose) is also approved in the European Union and the United States to treat androgen deprivation-induced bone loss in men with prostate cancer. In addition, preclinical rationale and emerging clinical data suggest that bone-modifying agents may be able to delay disease progression in genitourinary cancers, just as newly developed anticancer treatments have produced reductions in SREs, possibly by indirect effects on the disease course. This review article summarizes current data and ongoing studies to preserve bone health in patients with advanced genitourinary cancers. Keywords 441234T AU 421756287212441234M Aapro and F SaadTherapeutic Advances in Urology 2012Therapeutic Advances in Urology 4 (2) 86 http://tau.sagepub.com tumor-stimulating growth factors from the bone [Mundy, 2002]. The resulting vicious cycle of cancer growth and bone destruction can lead to skeletal-related events (SREs), including pathologic fractures, spinal cord compression, the need for palliative radiotherapy, surgery to bone, cementoplasty, and hypercalcemia of malignancy [Coleman, 2001]. Without bone-directed treatment, the majority of patients with advanced PC will experience an SRE during the course of their disease [Saad et al. 2004]. Moreover, in retrospective analyses of a 21-month, randomized, phase III, placebo-controlled trial in patients with bone metastases from solid tumors (excluding breast or prostate cancer) [Rosen et al. 2004], approximately 75% of patients in the RCC subset who did not receive bisphosphonate (BP) therapy developed an SRE [Saad and Lipton, 2005].Even before the development of bone metastases, bone health may be compromised in patients with GU cancers because of age-related osteoporosis and the detrimental effects of anticancer therapies on bone mineral density (BMD). This is most evident in the PC setting, wherein surgical or hormonal castration (androgen-deprivation therapy [ADT]) to lower testosterone levels is common in patients who have high-risk disease, or whose pros...

show abstract

Risedronate Recovers Bone Loss in Patients With Prostate Cancer Undergoing Androgen-deprivation Therapy

Cited by 28 publications

References 26 publications

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone‐releasing hormone‐agonist therapy for prostate cancer

Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid

Contact Info

Product

Resources

About